Share with friends :  The National Agency for Food and Drug Administration and Control ( NAFDAC ) has ordered drug manufacturing companies in Nigeria to immediately commence the production of chloroquine for the treatment of novel coronavirus disease ( COVID-19 ) .
Director-General of NAFDAC , Prof .
Mojisola Adeyeye disclosed this in a statement issued on Monday .
According to the statement , the drug that became well-known for being an anti-malaria drug is now being repurposed for use in the treatment of COVID-19 , which has already infected 111 Nigerians as of Sunday , March 29 .
She said the clinical trials of chloroquine for treatment of COVID-19 would commence in Lagos , the epicentre of the disease in Nigeria .
" In a very recent publication , chloroquine was reported in a press briefing by the State Council of China , indicating that chloroquine phosphate had demonstrated marked efficacy and acceptable safety in treating COVID-19 associated pneumonia in a multi-center clinical trials conducted in China .
" The study involved 10 hospitals in Wuhan , Jingzhou , Guangzhou , Beijing , Shanghai , Chongqing and Ningbo , and 100 patients @ @ @ @ @ @ @ @ @ @ the control in inhibiting the pneumonia associated with COVID-19 , and shortening the course of the disease , " the NAFDAC boss said .
She disclosed , " About four weeks ago , I approached a local manufacturing company ( May and Baker ) , a member of Pharmaceutical Manufacturing Group of Manufacturing Association of Nigeria ( PMGMAN ) , whose flagship product in the past was chloroquine to make a batch of the drug for emergency stock .
" The company had NAFDAC approval for the production of the drug as antimalarial many years ago before the discontinuation .
" The Managing Director expressed possible difficulty in getting the API due to the fact that the drug has been discontinued .
He called shortly after that he was able to get the API and was asked to manufacture a batch for emergency stock just in case more people become exposed and infected with the virus .
The batch has been manufactured and the company plans to make more batches if needed .
"  Adeyeye urged members of the public to " desist from its use @ @ @ @ @ @ @ @ @ @ cases of clinical trial treatment of COVID-19 " .
The NAFDAC boss stressed that side effects of the drug include gastrointestinal upset , blurred vision , headache , and pruritis ( itching ) , noting that prolonged use could also cause retinopathy or vision impairment .
